entertainment -WSS

entertainment

author：hotspot 2025-09-27 22:48:33 - browse：85

Marc Tessier Lavigne (center) retracted two Science papers on the day his resignation as Stanford president takes effect. Mattarella in San Francisco

After an expansive investigation found manipulated data and other issues with papers co-authored by Stanford’s now ex-president Marc Tessier-Lavigne, the prominent neuroscientist on Thursday retracted two studies published in the journal Science in 2001 — over the objection of a former postdoctoral researcher who played a leading role in both projects.

The retractions come the same day that Tessier-Lavigne’s resignation as Stanford president takes effect. His departure was prompted by a 95-page report released by a special committee of the university’s Board of Trustees, which recruited outside scientists and a former federal judge to investigate a dozen papers Tessier-Lavigne co-authored between 1999 and 2009, years before becoming the university’s leader.

The panel concluded that he did not personally engage in scientific misconduct, but it uncovered manipulated data in some studies Tessier-Lavigne had supervised and found that he took insufficient steps to “decisively and forthrightly” correct these studies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Hospitals consider fixing cancer drug shortages on their own

WSS

Food makers tried to stack nutrition panel with preferred experts

Akili changes sales model for its ADHD video game treatment

Akili changes sales model for its ADHD video game treatment

How to make the FDA’s new prescription one

How to make the FDA’s new prescription one

Chamber of Commerce, DOJ clash in court over drug prices

focus

entertainment

explore

Medical records are filled with copy

Regeneron agrees to White House price limits on anti

Walensky prepares to leave CDC — and Congress — behind

IRA could hurt research into orphan drugs for rare diseases

Novavax promises a turnaround & Lilly roils the obesity market

How medical schools plan to diversify without affirmative action

New air purifier tech could be key to improving indoor air quality

Food makers to regulators: Ultra

23andMe had bad news about my health. I wish a person had delivered it

How to make the FDA’s new prescription one

focus

Information blocking fines are now fair game in health care

FDA proposes changes to key medical devices approval pathway

Midwives could help bridge maternal health disparities in the U.S.

Regeneron agrees to White House price limits on anti

PEPFAR is under serious threat — and so is global health

Covid’s new normal has set in amid another rise in cases

Wikipedia

hotspot

focus

leisure time